NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory
Further Enhances Research Capabilities in Infectious Disease and Biodefense
DURHAM, N.C., Aug. 23, 2022 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the construction of an advanced biosafety level 2 (BSL-2) laboratory, adding biodefense and infectious disease capabilities to the Company’s research facilities in Research Triangle Park, North Carolina.
Jeff Wolf, NightHawk’s CEO, commented, “Given the unprecedented global biological threats facing our nation, both natural and man-made, this new, state-of-the-art BSL-2 laboratory will enable us to work with select attenuated agents such as anthrax and botulinum toxins, tularemia, monkeypox and other priority DOD agents and pathogens of global concern. The buildout of this facility follows our acquisition of biodefense company Elusys Therapeutics and represents the next stage in our efforts to develop medical countermeasures to protect the population against emerging biothreats.”
Matthew M. Seavey, PhD, Vice President of Research of NightHawk commented, “This new BSL-2 facility is being designed to accommodate research on high-priority infectious agents. As such, we are implementing strict safety measures within this facility, including enhanced safety monitoring, independent powered air filtration units (PAPR), HEPA filtered unidirectional HVAC units, and high security restricted access for secure entry, all measures that are critical for the BSL-2 classification. In addition, we have increased our vivarium footprint, allowing us to execute and enhance data generation related to infectious disease preclinical studies, in order to evaluate the efficacy, immunogenicity, and safety of vaccines and therapeutics against bacterial and viral pathogens.”
NightHawk Biosciences, Inc.
NightHawk Biosciences is a fully-integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization. The Company leverages its integrated ecosystem of subsidiaries to accelerate the development of novel therapies that arm the immune system, breaking through barriers that prolong traditional drug development. This empowers us to bring our ideas to life with efficient control, superior quality, and uncharacteristic agility.
For more information on the Company and is subsidiaries, please visit: www.nighthawkbio.com, and also follow us on Twitter.
Forward Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements such as the state-of-the-art BSL-2 laboratory enabling us to work with select attenuated agents such as anthrax and botulinum toxins, tularemia, monkeypox and other priority DOD agents and pathogens of global concern, and increasing the Company’s vivarium footprint, allowing it to execute and enhance data generation related to infectious disease preclinical studies, in order to evaluate the efficacy, immunogenicity, and safety of vaccines and therapeutics against bacterial and viral pathogens. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to work with select attenuated agents such as anthrax and botulinum toxins, tularemia, monkeypox and other priority DOD agents and pathogens of global concern at the state-of-the-art BSL-2 laboratory and the Company’s ability to execute and enhance data generation related to infectious disease preclinical studies, in order to evaluate the efficacy, immunogenicity, and safety of vaccines and therapeutics against bacterial and viral pathogens, NightHawk’s ability to commence operation in San Antonio and Kansas when anticipated and to successfully operate as a CDMO, NightHawk’s and its subsidiaries’ ability to maintain license agreements, the continued maintenance and growth of NightHawk’s and its subsidiaries’ patent estates, NightHawk’s product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior results, the ability to initiate clinical trials and if initiated, the ability to complete them on time and achieve the desired results and benefits continuing enrollment as expected, the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to NightHawk’s ability to promote or commercialize its product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of NightHawk’s products, developments by competitors that render such products obsolete or non-competitive, and other factors described in NightHawk’s annual report on Form 10-K for the year ended December 31, 2021, subsequent quarterly reports on Form 10-Qs and any other filings NightHawk makes with the SEC. The information in this presentation is provided only as of the date presented, and NightHawk undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
investorrelations@heatbio.com
